SCHEMBL16495474

SCHEMBL16495474

CN(C)CC(C)(C)CNC(=O)c1ccc(-c2ccc(F)cc2)nc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 6/20 0.52
HTR2C P28335 4/20 0.52
NPC1 O15118 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
PTPN1 P18031 1/20 0.48
PTPN6 P29350 1/20 0.48
PTPN11 Q06124 1/20 0.48
HPGDS O60760 1/20 0.44
GABRA5 P31644 5/20 0.43
KCNA3 P22001 1/20 0.43
BAZ2B Q9UIF8 1/20 0.42
HDAC2 Q92769 1/20 0.41
BUB1 O43683 1/20 0.41
CYP2C9 P11712 1/20 0.41
PRKACG P22612 1/20 0.41
MAPKAPK2 P49137 1/20 0.41
MAPK11 Q15759 1/20 0.41
MAPK14 Q16539 1/20 0.41
ACSL5 Q9ULC5 1/20 0.41
STK24 Q9Y6E0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16495554 0.88 HPGDS (0.58) MCHR1HTR2CHPGDSGABRA5BAZ2B
SCHEMBL16495688 0.87 HPGDS (0.53) MCHR1HTR2CHPGDSGABRA5BAZ2B
SCHEMBL16495501 0.81 RXFP1 (0.52) MCHR1HTR2CNPC1RXFP1PTPN1
SCHEMBL16495892 0.81 HPGDS (0.45) MCHR1HTR2CHPGDSGABRA5BAZ2B
SCHEMBL16495844 0.81 MCHR1 (0.55) MCHR1HTR2CNPC1RXFP1PTPN1
SCHEMBL16495808 0.79 HPGDS (0.51) HPGDSPRKACG
SCHEMBL16495734 0.79 NPC1 (0.55) MCHR1HTR2CNPC1RXFP1PTPN1
SCHEMBL16495499 0.77 RXFP1 (0.56) MCHR1HTR2CNPC1RXFP1PTPN1
SCHEMBL16496111 0.76 NPC1 (0.57) MCHR1HTR2CNPC1RXFP1PTPN1
SCHEMBL16496066 0.75 HPGDS (0.71) MCHR1HTR2CNPC1RXFP1PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110306597-A1 Nicotinamide Derivatives CRAWFORTH JAMES MICHAEL (GB) 2011-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306597-A1 Nicotinamide Derivatives NNT, NAMPT, NQO1 MCHR1 3398/4885HTR2C 3209/4885NPC1 236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.